BIVI
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
BioVie Inc. (BIVI) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C-). The rating has held at C for 10 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C- (2.0) | C- (2.1) | B- (3.0) | C+ (2.6) | C (2.4) |
| 2026-11-10 | C+ (2.5) | C- (2.0) | C- (2.0) | B- (3.1) | C+ (2.6) | C (2.4) |
| 2026-11-03 | C+ (2.5) | C- (1.9) | C- (2.1) | C- (2.1) | C+ (2.7) | C (2.3) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | C- (2.1) | C+ (2.7) | C+ (2.6) | C (2.4) |
| 2026-10-20 | C+ (2.5) | C- (1.9) | C- (2.1) | C+ (2.8) | C+ (2.6) | C (2.4) |